15 th Annual Indy Hematology Review

Transcription

1 15 th Annual Indy Hematology Review Saturday, March 10, 2018 JW Marriott Indianapolis 10 S. West Street Indianapolis, IN Presented by: Organized by: Indy Hematology Education, Inc. This Symposium is approved for 8.5 AMA PRA Category 1 Credit(s) TM by the Indiana Association of Pathologists, 7.75 CNE contact hours by the Ohio Nurses Association, and 7.75 CPE contact hours by the Purdue University College of Pharmacy

2 Gain knowledge that will immediately impact your practice. This full-day symposium features the nation s top experts in the field, comprehensive clinical content, the latest clinical research, and opportunities to interact with colleagues and vendors in an intimate group setting. A full day of presentations by today s leaders in Hematology and Hematologic Malignancies Accredited by the Indiana Association of Pathologists, this CME program has been designed to include content pertinent to the entire cancer care team; including hematologists and oncologists, physician assistants, nurse practitioners, nurses, pharmacists, researchers, and other healthcare professionals. The program features highly intensive sessions that showcase each speaker s evidence-based treatment approaches, present cutting-edge scientific data that can be translated into new strategies for diagnosis and treatment, and addresses challenging patient care questions. Dive deeper into new advances and targeted treatments for: Chronic and Acute Leukemias Indolent Lymphomas and aggressive non- Hodgkin s Lymphomas Hodgkin s Lymphoma Multiple Myeloma Myeloproliferative neoplasms Myelodysplastic syndromes Hematopoietic Stem Cell Transplantation Benign and non-benign hematology After participating in dynamic discussions with both experienced faculty and peers, you ll leave this symposium with the resources and knowledge on how to use these innovative therapies as well as the experts insights to help you provide optimal patient care.

3 SUPPORTERS & SPONSORSHIPS PLANNING COMMITTEE Ruemu Birhiray, MD (Chair) CEO, Indy Hematology Education Inc. Partner and Vice President, Hematology Oncology of Indiana, PC Michael C. Wiemann, MD (Co-Chair) Providence Hospital/St. John Health Senior VP, CMO Donna Birhiray, OTR, MBA Indy Hematology Education Inc. Treasurer Thalia Hammond Indy Hematology Education Inc. Linda Nielsen, DNP, APN Hematology Oncology of Indiana, PC The 2018 INDY Hematology Review is supported by an educational grant from: Astrazeneca Bayer Celgene Lilly Seattle Genetics Indy Hematology Education, Inc, is a 501(c), non-profit corporation, incorporated on February 15, 2010, in the State of Indiana, with the following purposes: (a) Raise awareness and provide education regarding hematology and oncology diseases and disorders (b) To encourage youth to pursue careers in hematology and oncology and (c) To connect individuals suffering from or affected by hematology and oncology diseases and disorders to organizations, programs and service providers. Jennifer Wheeler-Terry, JD Wabash College Debbie Locklear Meeting Services Unlimited Inc. President Tina Machina, CMP Meeting Services Unlimited Inc. Director of Conventions BOARD OF DIRECTORS RUEMU E. BIRHIRAY, MD, PRESIDENT AND CEO. MICHAEL WIEMANN, MD, VICE-PRESIDENT JENNIFER TERRY, JD, SECRETARY AND DIRECTOR DONNA M. BIRHIRAY, OT, MBA, TREASURER AND DIRECTOR THALIA HAMMOND, DIRECTOR

4 MAIN SYMPOSIUM AGENDA 7:00 AM - 2:30 PM Registration 7:00 AM - 5:00 PM Exhibit displays 7:30 AM Breakfast: Product Theaters 8:30 AM State of the Art: Treatments, Targets, and Diagnosis Ruemu E. Birhiray, MD Chair CEO, Indy Hematology Education Inc. Associate Professor of Clinical Medicine, Marian University of Osteopathic Medicine Partner and Vice President, Hematology Oncology of Indiana, PC (Indianapolis, IN) 9:00 AM Multiple Myeloma: Emerging Therapies Kenneth Anderson, MD Kraft Family Professor of Medicine, Harvard Medical School Program Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (Boston, MA) 9:30 AM Multiple Myeloma: What I recommend and how you should treat Paul Richardson, MD R.J. Corman Professor of Medicine, Harvard Medical School Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (Boston, MA) 10:00 AM Waldenström s Macroglobulinemia: Emerging options and current treatment paradigms Steven Treon, MD, MA, PhD Associate Professor of Medicine, Harvard Medical School Senior Attending Physician for Medical Oncology at DFCI and Brigham & Women's Hospital Director of the Bing Center for Waldenström s Macroglobulinemia Dana-Farber Cancer Institute (Boston, MA) 10:30 AM Break with Q & A 10:45 AM Not so Benign Hematology Robert Brodsky, MD Director of Division of Hematology Johns Hopkins Family Professor of Medicine and Oncology Johns Hopkins University School of Medicine (Baltimore, MD) 11:15 AM Benign Hematology: Coagulopathies and Beyond Craig Kessler, MD Professor of Medicine and Pathology Director of Clinical Coagulation Laboratory in Division of Laboratory Medicine Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital (Washington, DC) 11:45 AM Indolent Lymphomas and Hodgkin s Lymphoma: My treatment and emerging strategies Bruce Cheson, MD, FACP, FAAS, FASCO Deputy Chief of Division of Hematology and Oncology Head of Hematology and Professor of Medicine Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital (Washington, DC) 12:15 PM Aggressive B and T Cell Lymphomas: Treatment Paradigms in 2018 John Leonard, MD Attending Physician, New York-Presbyterian Hospital Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean of Clinical Research and Interim Chair of Department of Medicine Weill Cornell Medical College (New York, NY) 12:45 PM Q & A 1:00 PM Lunch: Product Theaters 2:00 PM T. HOWARD LEE KEYNOTE LECTURE Chronic Lymphocytic Leukemia: Targets, Treatments, and Resistance Thomas Kipps, MD, PhD Professor of Medicine Deputy Director of Research Operations and Interim Director UC San Diego Moores Cancer Center (San Diego, CA) 3:00 PM Challenging Cases Presentation Michael C. Wiemann, MD Co-Chair Providence Hospital/St. John Health Senior VP, CMO (Warren, MI)

5 3:05 PM Chronic Myeloid Leukemia Richard Larson, MD Professor of Medicine in Section of Hematology/ Oncology, Director of Hematologic Malignancies Clinical Research Program University of Chicago Comprehensive Cancer Center (Chicago, IL) 3:35 PM Beyond JAK 2: Mastocytosis, CMML, Eosinophilic and Neutrophilic Leukemia; Treatments, Paradigms, and Diagnosis Ayalew Tefferi, MD, PhD Professor of Hematology and Internal Medicine Mayo Clinic (Rochester, MN) 4:05 PM Myeloproliferative Neoplasms: What about JAK? PV, ET, MF John Mascarenhas, MD, MS Associate Professor of Medicine for Myeloproliferative Disorders Program Tisch Cancer Institute, Icahn School of Medicine Mount Sinai Medical Center (New York, NY) 5:15 PM Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: CARS, CARTS, Mechanics, and Beyond Elias Jabbour, MD, MA Associate Professor of Medicine, Department of Leukemia Section Chief of Acute Lymphocytic Leukemia The University of Texas MD Anderson Cancer Center (Houston, TX) 5:45 PM Hematopoietic Stem Cell Transplantation: How I treat and when I transplant in 2018 Richard Childs, MD, RADM, USPHS Senior Investigator for Laboratory of Transplantation Immunotherapy Clinical Director, National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (Bethesda, MD) 6:15 PM Q&A and Raffle 6:30 PM Wrap Up and Adjourn 4:35 PM Break with Q & A 4:45 PM Acute Myeloid Leukemias: Targets and Curability, So close but a journey so far Martin Tallman, MD Chief of Leukemia Service and Professor of Medicine Memorial Sloan-Kettering Cancer Center Weill Cornell Medical College (New York, NY) NURSING SYMPOSIUM AGENDA 9:00 AM Lymphoma Bruce Cheson, MD, FACP, FAAS, FASCO 9:30 AM Benign Hematology and Coagulopathy Craig Kessler, MD 10:00 AM Chronic Leukemias Richard Larson, MD 10:30 AM Break with Q & A 11:45 AM Not so Benign Hematology: Complementopathies and Aplastic Anemia Robert Brodsky, MD 12:15 PM Recognition and Management of Toxicities of Oral Therapeutics in Hematologic Malignancies Linda Nielsen, DNP, APN Hematology Oncology of Indiana (Indianapolis, IN) 12:45 PM Break with Q & A 10:45 AM Myeloma Paul Richardson, MD 11:15 AM Myeloproliferative Neoplasms Ayalew Tefferi, MD, PhD 1:00 PM Lunch: Product Theaters 2:00 PM Adjourn and join General Session for T. Howard Lee Lecture Disclosure information, biographies, and slides (where authorized by the presenter) will be available at indyhematologyreview.com

6 REGISTRATION To register online, go to indyhematologyreview.com and click on Register. Early Bird Registration: ends February 2, 2018 Early Bird Physicians $ Early Bird Physicians + CME Fee $ Early Bird Allied Health, Nurses, Pharmacists $ Early Bird Allied Health & Nurses + CNE Fee $ Early Bird Pharmacists + CPE Fee $ Industry & Exhibitors $ Standard Registration: after February 2, 2018 Physicians $ Physicians + CME Fee $ Allied Health, Nurses, Pharmacists $ Allied Health & Nurses + CNE Fee $ Pharmacists + CPE Fee $ Industry & Exhibitors $ Scholarships* for Nurses, Students, Residents, and Fellows $25.00 *A limited number of scholarships are available on a first-come, first-served basis. If you are registering clinicians in your office, ensure that you fill in the attendee s full name and correct address so that the post-event survey and continuing education credits are ed to the attendee. REFUND POLICY Request a registration cancellation refund on or before March 1, 2018, to receive a Full Refund. After March 1, there is NO REFUND. HOTEL RESERVATIONS To make reservations online, go to indyhematologyreview.com and click on Hotel/Parking. You can call the JW Marriott Indianapolis directly at or toll free at Mention Indy Hematology Review for the discounted group rate of $186 plus tax (currently 17%). The block of discounted rooms will be released on Friday, February 16, Make your reservation early. PARKING Parking is available at the JW Marriott Indianapolis. 24-hour parking rates are currently: $43 on-site parking; $48 valet. *Rates are subject to change without notice. QUESTIONS? Please contact Erica Olivero, , erica@conventionmanagers.com.

7 CONTINUING EDUCATION INFORMATION PHYSICIANS AND PHYSICIAN ASSISTANTS NURSES LEARNING OBJECTIVES At the completion of this activity, participants should be able to: Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promylelocytic and Myeloid Leukemia, and Myeloproliferative disorders. Recognize molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström s Macroglobulinemia to assist in disease recognition. Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeting in Atlanta, Georgia in December Identify new regimens for Hematopoietic Stem Cell transplantation and identification of transplant candidates. Review the advancement in benign hematology research. Review new treatment regimens in chronic Lymphocytic Leukemia. CME ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Indiana Association of Pathologists and Indy Hematology Education, Inc. The Indiana Association of Pathologists is accredited by the Indiana State Medical Association to provide continuing medical education for physicians. DESIGNATION STATEMENT The Indiana Association of Pathologists designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. DISCLOSURE STATEMENT In accordance with the ACCME Standards for Commercial Support, educational programs sponsored by the Indiana Association of Pathologists (IAP) must demonstrate balance, independence, objectivity and scientific rigor. Prior to the activity, all faculty, authors, editors and planning committee members participating in an IAP-sponsored activity are required to disclose to attendees any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. CNE ACCREDITATION STATEMENT This continuing nursing education activity was approved by the Ohio Nurses Association (OBN ), an accredited approver by the American Nurses Credentialing Center s Commission on Accreditation. Approval valid through Assigned ONA #21199 This program is approved for 7.75 contact hours. PHARMACISTS CPE ACCREDITATION STATEMENT Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): L01-P This program is approved for 7.75 contact hours (0.775 CEU s). PHARMACY LEARNING OBJECTIVES At the completion of this activity, participants should be able to: Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promylelocytic and Myeloid Leukemia, and Myeloproliferative disorders. Recognize molecular diagnosis, targeted therapies, and resistance of mechanisms of Waldenström s Macroglobulinemia to assist in disease recognition. Discuss the advancement of immune check point inhibitors within hematologic malignancies. Identify new regimens of Hematopoietic Stem Cell transplantation and identification of transplant candidates. Review the advancement in benign hematology research. NOTE: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

8 Indy Hematology Review C/O Meeting Services Unlimited 135 S. Mitthoeffer Rd. Indianapolis, IN Presented by: 15 th Annual Indy Hematology Review Saturday, March 10, 2018 JW Marriott Indianapolis 10 S. West Street Indianapolis, IN